DEFINIUM THERAPEUTICS INC (DFTX)
Sector: Health Care
2026 Annual Meeting Analysis
DEFINIUM THERAPEUTICS INC · Meeting: June 11, 2026
Directors FOR
7
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors to hold office until the 2027 annual general meeting of shareholders
Vallone has served since September 2021 and the company's 3-year price return of +431.1% outperforms XBI (the SPDR S&P Biotech ETF) by +364.3 percentage points, far exceeding the 65pp threshold required to trigger a negative vote; no overboarding, independence, attendance, or qualification concerns were identified.
Krebs has served since September 2021 and the company's 3-year return vastly outperforms XBI (the SPDR S&P Biotech ETF) by +364.3pp, well above the 65pp trigger threshold; he attended 100% of board and committee meetings and has relevant pharmaceutical and investment experience.
Bruhn has served since August 2022 and the company's strong 3-year TSR relative to XBI (the SPDR S&P Biotech ETF) means the underperformance trigger does not apply; she holds two other public board seats (Travere Therapeutics and Pliant Therapeutics), which is within the four-seat overboarding limit, and she attended 100% of meetings.
Crystal has served since August 2022 and the TSR trigger does not apply given the company's +431.1% 3-year return versus XBI (the SPDR S&P Biotech ETF); while he holds CEO roles at FoldLogic Bio and W12 Therapeutics (both private companies), no evidence of overboarding at public companies was identified, and he attended 86% of board meetings, meeting the 75% threshold.
Gryska has served since June 2023 and the TSR trigger does not apply; he is the Audit Committee Chair with clear financial expertise as a former CFO of multiple public biotech companies, attended 100% of meetings, and holds only one other public board seat.
Adsett joined the board in January 2026, less than 24 months ago, and is therefore exempt from the TSR trigger under the new-director exemption; he brings relevant commercial launch experience at a public biopharmaceutical company and is independent.
Barrow is the CEO and has served as a director since December 2021; the company's 3-year TSR of +431.1% outperforms XBI (the SPDR S&P Biotech ETF) by +364.3pp, far exceeding the 65pp trigger threshold, so no TSR-based concern applies, and no other governance flags were identified.
All seven director nominees receive a FOR vote. The company's 3-year stock return of +431.1% dramatically outperforms XBI (the SPDR S&P Biotech ETF) by +364.3 percentage points, which is well above the 65-percentage-point threshold required to trigger a negative vote on performance grounds. No overboarding, independence, attendance, qualification, or familial relationship concerns were identified across the slate. Roger Adsett, who joined in January 2026, is exempt from TSR analysis as a new director within his first 24 months.
Say on Pay
✓ FORCEO
Robert Barrow
Total Comp
$12,767,442
Prior Support
N/A
Note: This filing does not include a standalone Say on Pay (executive compensation advisory vote) proposal — Proposal 3 is an equity plan amendment, not a Say on Pay vote. The CEO compensation of $12,767,442 is noted for context; the company emphasizes that a significant portion of named executive officer pay is performance-based equity, which is consistent with good pay-mix practices. Because no Say on Pay proposal appears on this ballot, no vote determination on executive compensation can be rendered, and this entry reflects the equity plan amendment proposal that is actually Proposal 3 on this ballot.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
4 yrs
Audit Fees
$960,000
Non-Audit Fees
$146,000
KPMG's non-audit fees (tax and other fees totaling $146,000) represent approximately 15.2% of audit fees ($960,000), which is well below the 50% threshold that would raise independence concerns; KPMG has audited Definium since 2022 (approximately 4 years), far below the 25-year tenure threshold; no material financial restatements were identified; and KPMG is a Big 4 firm appropriate for a $2.1B market cap company.
Overall Assessment
This is a straightforward annual meeting ballot with three proposals: election of seven directors, ratification of KPMG as auditor, and approval of an equity plan share increase. The company's exceptional stock performance — a 3-year return of +431.1% versus +66.8% for XBI (the SPDR S&P Biotech ETF) — means no TSR-based concerns apply to any director, KPMG's fee structure and tenure are clean, and no Say on Pay vote appears on this ballot.